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BACKGROUND: The most important prognostic factors for survival in patients with metastatic renal cell carcinoma (mRCC) were
evaluated in the era of cytokine therapy, and only recently were revalidating in patients receiving targeted therapies (TTs).
METHODS: Clinical data for consecutive patients with mRCC who received TTs were retrieved from the database of Istituto Nazionale
dei Tumori of Milan. Variables with a significant association with overall survival (OS) were estimated by proportional hazard
regression, and a backward stepwise multivariate analysis identified the independent prognostic factors.
RESULTS: Data for 336 consecutive patients treated with TTs for RCC during the period 2004–2011 were evaluated. According to the
Motzer classification, 32% patients were low risk, 48% were intermediate risk and 20% were poor risk. One hundred and sixty-seven
(49.7%) patients received one TT, 116 (34.5%) received a second-line TT, 42 (12.5%) a third-line TT and 11 (3.3%) patients received
a fourth-line TT. The median OS was 24 months (95% CI 20.0, 27.0) and the 5-year OS rate was 24.6% (95% CI 18.7, 30.8%). In the
uni- and multivariate analysis Motzer risk classification, Fuhrman grade and previous cytokine therapy were identified as independent
prognostic factors (Po0.01).
CONCLUSION: The Motzer classification was confirmed as an independent prognostic factor for OS in patients with mRCC receiving
TTs. Additionally, Fuhrman grade and previous cytokine therapy were independent prognostic factors for clinical outcome.
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The management of metastatic renal cell carcinoma (mRCC) has
been revolutionized, with targeted therapies (TTs) superseding
cytokine therapy (interferon-a and interleukin-2). Indeed, because
of the number of therapies now available, the identification
of prognostic factors has an important role in the clinical
management of the advanced disease (Heng et al, 2009; Volpe
and Patard, 2010).
Prognostic factors allow a homogeneous stratification of
patients in clinical trials, avoiding the identification of any group
in which a TT has greater activity, which would constitute
a selection bias (Motzer et al, 2000).
In the cytokine era, the most commonly used prognostic criteria
have been those developed by Motzer, who assessed 670 patients
enroled in clinical trials of immunotherapy and chemotherapy at
the Memorial Sloan Kettering Cancer Centre (Motzer et al, 1999).
The multivariate analysis has revealed that haemoglobin,
serum lactate dehydrogenase, corrected serum calcium level,
nephrectomy status and Karnofsky Performance Status (PS) were
independent risk factors for prediction of survival.
Using a combination of these factors, patients were stratified as
being of favourable, intermediate or poor risk, with mean survival
times of 20, 10 and 4 months, respectively.
The predictive role of this model has been successfully validated,
with some modifications, by a retrospective analysis that included
353 patients with mRCC at the Cleveland Clinic (Mekhail et al,
2005).
This study confirms the prognostic role for all factors identified
by Motzer, with the exclusion of PS, and reveals two more
prognostic factors: prior radiotherapy and number of sites
of metastases.Reported median survival times were 26.0, 14.4
and 7.3 months, respectively (Mekhail et al, 2005).
Despite their validation only in patients treated with cytokines,
these models have also frequently been used to assess the risk of
death in patients treated with TTs in major phase II–III trials in
mRCC.
Choueiri et al (2007) proposed a new classification for patients
receiving antiangiogenic agents, confirming the independent
predictive role for Eastern Cooperative Oncology Group (ECOG)
PS, time from diagnosis to current treatment and abnormal
baseline-corrected serum calcium and revealing higher platelet and
absolute neutrophil counts as two new prognostic factors.
Similar to the previous classification, patients were grouped
according to the number of prognostic factors (p1, 2 or X3
prognostic factors) and a difference in median overall survival
(mOS) was found (20.1, 13 and 3.9 months, respectively) (Choueiri
et al, 2007). The largest analysis in patients with mRCC treated
with TT was performed by Heng et al (2009). In this study, the role
of low haemoglobin, high serum-corrected calcium, Karnofsky PS
o80 and time from diagnosis to therapy initiation o1 year were
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confirmed as independent predictors of shorter survival. Further-
more the absolute neutrophil and platelet counts greater than the
upper limit of normal were also considered prognostic factors.
The mOS was not reached in the favourable-risk group, but was
27.0 and 8.8 months in the intermediate-risk and poor-risk groups,
respectively (Heng et al, 2009).
This study did not report a difference in outcomes with the use
of antiangiogenic therapy as first- or second-line therapy, and
confirms the poor prognosis for non-clear-cell histology, although
this factor was not included in the final model (Heng et al, 2009).
Recently Manola et al (2011) reported the results from the
International Kidney Cancer Working Group, which validated the
role of prognostic factors for survival in patients with mRCC. From
a comprehensive international database, data for 3748 patients
with mRCC were analysed to identify independent predictors of
survival.Nine clinical factors were considered in this analysis;
treatment, PS, number of metastatic sites, time from diagnosis to
treatment, pretreatment haemoglobin, white blood count, lactate
dehydrogenase, alkaline phosphatase and serum calcium.These
factors formed three risk groups using the 25th and 75th
percentiles of the resulting prognostic index.This model showed
good concordance among the 645 patients treated with tyrosine
kinase inhibitors (C statistic¼ 0.741; 95% CI 0.714, 0.768).
All these studies show that TTs have approximately doubled the
median survival in patients with mRCC compared with the data
reported by Motzer in the cytokine era (22 vs 10 months) and that
the efficacy of sequential TTs is independent of the treatment
sequence used.
Some questions remain unanswered; no factor has been reported
as prognostic for patients receiving mammalian target of
rapamycin inhibitors, and the role of nephrectomy is still
undefined as a prognostic factor in patients with mRCC receiving
TTs.
A series of consecutive patients with mRCC and treated with TTs
at IRCCS Istituto Nazionale dei Tumori in Milan were examined to
evaluate the role of several prognostic factors. The preliminary
results of this retrospective study have been published previously
(Procopio et al, 2011a).
MATERIALS AND METHODS
Patients
Consecutive patients with mRCC, aged X18 years and with
an ECOG PS of 0, 1 or 2, who were treated with one or more TTs,
were eligible for inclusion in this retrospective study. Baseline
characteristics and outcomes of patients were collected from the
database of Istituto Nazionale dei Tumori, Milan, Italy.
A number of patients enrolled in this study had previously taken
part in a range of prospective trials including TARGET (Escudier
et al, 2007a), the EU-ARCCS (Beck et al, 2011), RECORD-1
(Motzer et al, 2008), AXIS (Rini et al, 2011), AVOREN (Escudier
et al, 2007b) and ROSORC (Procopio et al, 2011b).
The study was conducted in accordance with the International
Conference on Harmonization for Good Clinical Practice (Dixon,
1998), and it was approved by the local ethics committee and
institutional review board.
Treatment and study assessments
All patients included in the final database received TT as first-line
treatment, or subsequent cytokine therapy. The TTs were:
sorafenib 400mg twice daily orally, sunitinib 50mg daily (4 weeks
on, 2 weeks off) orally, bevacizumab 10mg/kg intravenously every
2 weeks in combination with subcutaneous interferon-a, ever-
olimus 10mg daily orally, temsirolimus 25mg intravenously
weekly or axitinib 10mg daily orally. Patients received systemic
therapy until disease progression or the presence of serious
adverse events.
Statistical analyses
For the description of clinical, pathological and treatment
characteristics of the patients, categorical variables were described
using absolute and relative frequencies; continuous variables were
described using the median as a measure of central tendency and
the range as a measure of dispersion. w2 test for trend was
performed in order to determine whether Motzer classification was
a significant predictor of the number of therapy cycles. Overall
survival was defined as the time from initiation of treatment with
TTs to the date of death or last follow-up. The Kaplan–Meier
method was used to estimate survival probabilities; the inverse
Kaplan–Meier method was used to estimate the median follow-up;
the log-rank test was used to detect a statistically significant
difference in survival; the Cox regression model was used to
estimate hazard ratios (HRs) and to identify independent
prognostic factors by using a backward selection strategy; all the
baseline characteristics were introduced in the backward selection
algorithm. All statistical tests were two-sided and a P-value o0.05
was considered statistically significant; the same threshold was
used as the criterion for retaining variables in the backward
selection algorithm.. Statistical analysis was performed using SAS
software, version 9.2 (SAS Institute, Cary, NC, USA); the statistical
package Stata, version 12.0 (StataCorp, College Station, TX, USA)
was used for Kaplan–Meier plots.
RESULTS
Patients and treatments
A total of 336 patients with mRCC were treated with TTs at the
Istituto Nazionale dei Tumori in Milan between January 2004 and
October 2011 (Supplementary Figure 1, flow chart). Patient
characteristics at baseline are shown in Table 1. For the definition
of Motzer risk groups the following factors were considered: ECOG
PS status as 0 vs 1 and above, nephrectomy status, HgB, LDH and
corrected calcium. Similar to the previous classification, patients
were grouped according to the number of prognostic factors
(0, 1–2 or X3) in low, intermediate and poor risk, respectively.
According to the Motzer classification 108 (32%) patients were
low risk, 159 (48%) intermediate and 66 (20%) poor risk
Nine patients were excluded from survival analysis: seven
patients with Bellini duct carcinoma characterised by an aggressive
course and two patients because survival outcome was
not available. Patients were followed for a median of 43 months
(range 0.5–88.1 months). Median overall survival was 24 months
(95% CI: 20.0, 27.0) and the 5-year overall survival rate was
24.6% (95% CI: 18.7, 30.8) (Figure 1). Overall 199 (57%) patients
died.
One hundred and sixty-seven (49.7%) patients received only one
TT, 116 (34.5%) received a second-line TT, 42 (12.5%) a thirdline
and 11 (3.3%) patients received a fourth-line TT; overall 245
(72.9%) patients received sorafenib, 212 (63.1%) sunitinib, 33
(9.8%) bevacizumab and 73 (21.7%) another/other TT(s).
The majority of patients (n¼ 295, 87.8%) received sorafenib or
sunitinib as the first TT; of these, 205 (61.0%) patients received
sorafenib; of the remaining patients 28 (8.3%) received bevacizu-
mab, 8 (2.4%) temsirolimus, 3 (0.9%) bevacizumab in combination
with everolimus, 1 (0.3%) bevacizumab in combination with
erlotinib and, 1 (0.3%) pazopanib.With regard to second-line
treatment, sorafenib was followed by sunitinib in 101 out of 111
(91.0%) patients and sunitinib was followed by sorafenib in 19 out
of 29 (65.5%) patients.
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Treatment outcomes
Regarding the association between the Motzer classification and
the number of therapy cycles, a negative trend was detected
(w2¼ 10.718, P¼ 0.001); the median number of treatments was
two in the low and intermediate risk groups, and one in the
high-risk group. Regarding patients who received at least a second-
line therapy, there was no significant correlation between the
sequence of TT and survival (HRsunitinib-sorafenib/sorafenib-
sunitinib¼ 1.16; 95% CI: 0.57–2.33; HROther/sorafenib-sunitinib¼ 1.21;
95% CI: 0.78–1.88; P¼ 0.674) as presented in Table 2 and Figure 2.
Prognostic factors
At the univariate level, Motzer risk class, ECOG PS, nephrectomy,
Fuhrman grade, number of sites of disease and previous cytokine
treatment were predictive factors for survival, but there were no
differences based on tumour histology, age, sex or treatment
sequence (Table 2).
Median survival and 5-year overall survival rate according to the
Motzer criteria were 44 months (95% CI 33.0, 63.1) and 40.0%
(95% CI 28.4, 51.3) in low-risk patients, 22 months (95% CI 17.0,
27.0) and 21.4% (95% CI 12.8, 31.4) in intermediate-risk patients
and 9 months (95% CI 7.0, 11.0) and 0% in patients considered
high risk (Po0.001) (Figure 3A).
The multivariate analysis identified the following independent
prognostic factors: Motzer score (HRintermediate_vs_low¼ 2.39; 95%
CI 1.67, 3.41; HRhigh_vs_low¼ 7.41; 95% CI 4.89, 11.24; Po.001);
Fuhrman grade (HR3–4_vs_1–2¼ 1.59; 95% CI 1.19, 2.12; P¼ 0.002)
and previous cytokines (HRyes_vs_no¼ 1.50; 95% CI 1.13, 2.00;
P¼ 0.005). Adjusting for all baseline characteristics statistically
associated to overall survival nephrectomy confirmed its
prognostic role (HR¼ 0.52; 95% CI:0.32–0.82; P¼ 0.006)
(Figure 3B–D) (Supplementary Tables 1 and 2).
DISCUSSION
The high level of molecular and pathological heterogeneity in RCC
contributes to the varying prognoses and outcomes that char-
acterise this disease (Ljungberg et al, 1996). A more detailed
knowledge and understanding of the individual risk factors
that predict patient’s responses would be beneficial not only for
individual patient management and treatment choices, but also for
clinical trial design to ensure better definition of patient risk
groups (Ljungberg et al, 1996; Volpe and Patard, 2010).
Several prognostic factors have been established for the
outcomes of patients with advanced RCC. The majority of the
research on this topic applies to the treatment with cytokines,
interferon-a and interleukin-2 (Motzer et al, 1999, 2000, 2004;
Mekhail et al, 2005; Choueiri et al, 2007). With the subsequent
introduction of novel targeted anticancer therapies, the models of
prognostic factors are required to be revalidated for the new
treatments.
With regard to the new therapies for patients with mRCC,
Manola et al (2011) validated nine prognostic factors and
developed a prognostic model for survival, including three risk
groups (favourable, intermediate and poor) characterised by 26.9,
11.5 and 4.2 months of overall survival, respectively. This study
was the largest of its kind, validating the role of prognostic factors
in a population receiving TTs.
Table 1 Baseline characteristics of the patient population with metastatic
renal cell carcinoma treated with targeted therapies
Characteristics N %
Median age, years (range) 62 (25–82)
Sex
Male 248 73.8
Female 88 26.2
ECOG PS
0 186 55.4
1 131 39.0
2 19 5.7
Histology
Clear-cell 291 86.9
Non-clear cell 45 13.1
Papillary 29 65.9
Bellini 7 15.9
Chromophobe 7 15.9
Oncocytoma 1 2.3
Missing data 1 0.3
Previous nephrectomy
Yes 293 87.2
No 43 12.8
Fuhrman grade
1 15 5.1
2 99 33.8
3 131 44.7
4 48 16.4
Missing data 43 12.8
Motzer risk class
Low risk 108 32.4
Intermediate risk 159 47.7
High risk 66 19.8
Missing data 3 0.9
Number of disease sites
1 126 37.8
2 117 35.1
3 67 20.1
4 18 5.4
5 4 1.2
6 1 0.3
Missing data 3 0.9
Sites of disease (n¼ 659)
Bone 94 28.2
Brain 16 4.8
Liver 62 18.6
Lung 221 66.4
Lymph nodes 127 38.1
Pancreas 17 5.1
Thyroid 5 1.5
Other 117 35.1
Missing data 3 0.9
0 6
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Figure 1 Overall survival in patients with metastatic renal cell carcinoma
receiving targeted therapies.
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For patients receiving TTs (mostly sorafenib, sunitinib and
bevacizumab), our study highlighted the prognostic role of the
Motzer classification according to the uni- and multivariate
analyses. Similar to that previously reported by Heng et al
(2009), the mOS of patients described in this report was notably
increased compared with that demonstrated by Motzer et al
(1999).
The increased survival reported for patients with mRCC may
well be associated with the improvement of diagnostic and surgical
procedures and best supportive care, but it is also due to the
greater efficacy of the new systemic therapies. Moreover, this
survival improvement has been reported for all risk groups; the
mOS was 43, 21 and 8 months for favourable-, intermediate- and
poor-risk groups, respectively, which is double the overall survival
reported previously for patients treated with cytokines (20, 10 and
4 months, respectively) (Motzer et al, 2004).
There was no survival difference for different treatment
sequences or types of TTs received, as discussed in a previous
study (Procopio et al, 2011a, b).
Among the parameters of the Motzer risk classification, the
univariate analysis showed nephrectomy as an independent
variable prognostic factor for survival in patients treated with
TTs. The prognostic role of cytoreductive nephrectomy (CN) in
patients affected by mRCC was first reported by Motzer et al
(1999), and subsequently confirmed by two prospective studies,
which showed a longer overall survival with CN combined with
Table 2 Univariate overall survival analysis for patients with metastatic renal cell carcinoma treated with targeted therapies
Hazard ratio
Variable Categories Point estimate 95% CI v2 P-value
Baseline characteristics
Agea — 1.00 0.89, 1.13 0.002 0.964
Sex Female 1 0.153 0.695
Male 1.07 0.77, 1.48
ECOG PS 0 1 26.806 o0.001
1 1.84 1.37, 2.46
2 3.29 1.86, 5.81
Histologyb Clear-cell 1
Papillary 1.38 0.88, 2.18 2.012 0.366
Other 1.13 0.50, 2.54
Non clear-cell 1.32 0.88, 1.98 1.769 0.183
Nephrectomy No 1 8.556 0.003
Yes 0.52 0.34, 0.81
Previous cytokines No 1 6.239 0.012
Yes 1.43 1.08, 1.89
Fuhrman grade 1–2 1 11.829 o.001
3–4 1.64 1.24, 2.18
Motzer risk groups Low 1 77.636 o0.001
Intermediate 2.05 1.45, 2.91
High 7.27 4.80, 11.02
No. of disease sites 0–1 1 19.299 o0.001
2 1.86 1.32, 2.62
42 2.17 1.52, 3.09
Treatment
First-line SO 1 8.695 0.013
SU 0.53 0.35, 0.81
Other targeted therapies 0.82 0.52, 1.29
Sequential therapyc SO-SU 1 0.788 0.674
SU-SO 1.16 0.57, 2.33
Other sequences 1.21 0.78, 1.88
Abbreviations: CI¼ confidence interval; ECOG PS¼ Eastern Cooperative Oncology Group Performance Status; SO¼ sorafenib; SU¼ sunitinib. aAge in 10-year increments.
bTwo main histological classifications included. cIn patients receiving a second targeted therapy.
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Figure 2 Overall survival with sorafenib and sunitinib compared with
other therapies in patients with metastatic renal cell carcinoma.
Prognostic factors in metastatic RCC
G Procopio et al
1230
British Journal of Cancer (2012) 107(8), 1227 – 1232 & 2012 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
cytokine therapy than with systemic treatments alone (Flanigan
et al, 2001 and Mickisch et al, 2001).
Recently, the role of CN has been questioned, considering the
high-response rate and the improvement of survival achieved with
TTs (You et al, 2011). Although the prognostic role of previous
nephrectomy has been recently reported in patients with mRCC
treated with TTs (Choueiri et al, 2011; Yuasa et al, 2012), the
analysis of prognostic factors for patients enrolled in a phase III
trial of sunitinib failed to find it (Patil et al, 2011). Furthermore,
the role of CN on tumour control by TTs is also disputed, as two
large retrospective analyses report conflicting results (Choueiri
et al, 2011; Patil et al, 2011).
Our study, larger than that published by Yuasa et al (2012) and
similar to that of Choueiri et al (2011), regarding the number of
patients and the type of treatments, reports a survival benefit and
the independent prognostic role of CN in patients with mRCC
treated with TTs.
The current prognostic role of CN in patients with
mRCC treated with TTs is therefore not yet clearly defined and
probably only ongoing phase III trials will in time answer
this question (You et al, 2011). Proof of that considering only
our retrospective analysis patients who did not receive a CN
often had bad clinical conditions or multiple sites of disease and
bulky disease. Therefore, this last population had additional
unfavourable factors that could explain the worse prognosis of the
disease.
Additionally the uni- and multivariate analyses showed the
Fuhrman grade and previous therapy with cytokines as independent
factors of clinical outcome. In our experience, patients treated with
cytokines received too-late TTs for advanced disease, and often only
one antiangiogenic treatment, which could, in our opinion, justify
the worse prognosis of this subgroup of population.
Fuhrman grade is well-recognised to be an inde-
pendent prognostic factor for recurrence in patients
nephrectomised.
Our experience disclosed that also in advanced disease treated
with TTs, Fuhrman grade could have a role as independent
prognostic factor for outcome (see Tables 2 and 3).
Additionally, some factors, such as number of sites of disease
and number of TTs, were confirmed as prognostic factors only in
the univariate analysis, suggesting that they may be less relevant
(Table 2).
With this study being designed to elucidate prognostic factors in
mRCC, its retrospective design constitutes a distinct limitation on
the interpretation of results. Also not considered in this study
was the heterogeneity, which usually characterises mRCC and any
biological parameters.
In conclusion, the Motzer criteria were validated as prognostic
factors for survival in patients with mRCC receiving TTs.
Additionally, Fuhrman grade and use of previous cytokines were
independent prognostic factors of clinical outcome.
These data may be useful for improved patient management and
treatment decision making, as well as stratification of patient
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Figure 3 Overall survival in patients with metastatic renal cell carcinoma receiving targeted therapies stratified according to (A) Motzer classification,
(B) Eastern Cooperative Oncology Group performance status (ECOG PS), (C) nephrectomy status and (D) previous cytokine therapy.
Table 3 Multivariate overall survival analysis for patients with metastatic
renal cell carcinoma treated with targeted therapies
Hazard ratio
Variable Categories
Point
estimate 95% CI v2 P-value
Previous cytokine
therapy
No 1 7.909 0.005
Yes 1.50 1.131, 2.00
Fuhrman grade 1–2 1 10.008 0.002
3–4 1.59 1.193, 2.12
Motzer risk groups Low 1 89.712 o0.001
Intermediate 2.39 1.67, 3.41
High 7.41 4.89, 11.24
Abbreviation: CI¼ confidence interval.
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groups in clinical trials, for better interpretation and application of
outcomes of studies of TTs in patients with mRCC.
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